Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) was down 3.8% during mid-day trading on Thursday . The stock traded as low as $15.33 and last traded at $15.52, with a volume of 127,375 shares trading hands. The stock had previously closed at $16.14.

Several equities research analysts have weighed in on ADMS shares. JMP Securities started coverage on Adamas Pharmaceuticals in a research note on Friday, April 1st. They set an “outperform” rating and a $29.00 target price for the company. Mizuho upped their target price on Adamas Pharmaceuticals from $14.00 to $17.00 and gave the stock a “neutral” rating in a research note on Thursday, April 28th. Cowen and Company restated a “buy” rating on shares of Adamas Pharmaceuticals in a research note on Thursday, May 12th. Zacks Investment Research upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, May 16th. Finally, Piper Jaffray Cos. restated an “overweight” rating and set a $44.00 target price on shares of Adamas Pharmaceuticals in a research note on Tuesday, June 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the stock. Adamas Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $33.60.

The stock’s market capitalization is $334.57 million. The company’s 50-day moving average price is $16.32 and its 200 day moving average price is $16.97.

Adamas Pharmaceuticals (NASDAQ:ADMS) last released its quarterly earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.65) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.76) by $0.11. On average, equities analysts predict that Adamas Pharmaceuticals Inc. will post ($3.09) earnings per share for the current fiscal year.

In other news, SVP Natalie Mcclure sold 36,000 shares of the stock in a transaction on Monday, April 18th. The shares were sold at an average price of $18.50, for a total value of $666,000.00. Following the completion of the sale, the senior vice president now directly owns 21,006 shares of the company’s stock, valued at $388,611. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Several hedge funds have recently made changes to their positions in the company. Strs Ohio boosted its stake in shares of Adamas Pharmaceuticals by 46.9% in the fourth quarter. Strs Ohio now owns 39,800 shares of the specialty pharmaceutical company’s stock worth $1,127,000 after buying an additional 12,700 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Adamas Pharmaceuticals by 585.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 69,411 shares of the specialty pharmaceutical company’s stock worth $1,966,000 after buying an additional 59,285 shares during the period. Russell Frank Co boosted its stake in shares of Adamas Pharmaceuticals by 119.8% in the fourth quarter. Russell Frank Co now owns 83,773 shares of the specialty pharmaceutical company’s stock worth $2,395,000 after buying an additional 45,652 shares during the period. Finally, EAM Investors LLC purchased a new stake in shares of Adamas Pharmaceuticals during the fourth quarter worth about $4,006,000.

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.